Impulse Control Disorders
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
2 programsExperimentalN/A1 trial
Fingerprinting of ImpulsivityN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PfizerSertraline
Boehringer IngelheimExperimental
Boehringer IngelheimFingerprinting of Impulsivity
Clinical Trials (3)
Total enrollment: 264 patients across 3 trials
Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
Start: Jan 2000Est. completion: Aug 200475 patients
Phase 4Completed
fMRI in Impulsivity
Start: Jul 2016Est. completion: May 201848 patients
N/ACompleted
Fingerprinting of Impulsivity
Start: Jul 2016Est. completion: Sep 2018141 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.